会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 10. 发明公开
    • 바닐로이드 수용체 길항물질로서의 신규 화합물, 이의이성체 또는 이의 약학적으로 허용가능한 염, 및 이를함유하는 약학 조성물
    • 新化合物,其异构体,或其药学上可接受的盐作为VANILLOID受体拮抗剂; 和含有它们的药物组合物
    • KR1020080007329A
    • 2008-01-18
    • KR1020077024002
    • 2006-03-15
    • (주)아모레퍼시픽
    • 김희두서영거박형근오우택박설린김주현장미정박영호신송석김선영김진관정연수이기화최진규임경민고현주모주현김성일우병영
    • C07C275/24C07C275/18A61K31/17
    • C07C275/24C07C311/08C07C311/11C07C323/62C07D211/46C07D295/088C07D295/155C07D309/12C07F7/0818
    • A compound as a vanilloid receptor antagonist is provided to obtain a pharmaceutical composition effective for preventing or treating pain, migraine, arthralgia, nerve injury, skin diseases, overactive bladder, irritable bowel syndrome, or the like. A compound as a vanilloid receptor antagonist, an isomer or a pharmaceutically acceptable salt thereof is represented by the following formula I. In formula I, X is NHCH2, CR11=CR12, NH, CHR11CHR12 or C=C, wherein each of R11 and R12 represents H, halogen, C1-C5 alkyl, C1-C5 alkoxy, halo(C1-C5)alkyl or phenyl; R1 is a C2-C5 alkenyl or C2-C5 alkynyl; R2 is H, halogen, nitro, cyano, C1-C5 alkyl, C1-C5 alkoxy, halo(C1-C5)alkyl, C2-C5 alkenyl, or C2-C5 alkynyl; R2 is H, halogen, nitro, cyano, C1-C5 alkyl, C1-C5 alkoxy, halo(C1-C5)alkyl, C2-C5 alkenyl, C2-C5 alkynyl, carboxyl, C1-C5 alkoxycarbonyl, C1-C5 alkylthio, phenyl or phenyl(C1-C3)alkyl, wherein is each phenyl group is non-substituted or substituted with at least one substituent; R3 is H, C1-C5 alkyl, C1-C5 alkoxy or halo(C1-C5)alkyl; each of R4, R5 R6, R7 and R8 independently represents H, carboxyl, C1-C5 alkyl, nitro, C2-C5 alkenyl, C1-C5 alkoxy, C2-C5 alkynyl, halo(C1-C5)alkyl, C1-C5 alkylthio, C1-C5 alkylsulfonyl, C1-C5 alkylcarbonyl, C1-C5 alkoxycarbonyl, hydroxy, C2-C5 alkenyloxy, C1-C5 alkoxy(C1-C5)alkoxy, C1-C5 alkoxy(C1-C5)alkoxy(C1-C5)alkyl, C1-C3 alkylpiperazinyl, piperazinyl(C1-C5)alkoxy, piperidinyl(C1-C5)alkoxy, C1-C5 alkoxy (C1-C5)alkylamino, C1-C7 alkylamino, morpholinyl, morpholinyl(C1-C5)alkyloxy, tetrahydropyranyloxy, phenyl or halogen, wherein each phenyl group is non-substituted or substituted with at least one substituent; each of R9 and R10 independently represents H, -SO2R13, -SOR13, C1-C5 alkyl, C1-C5 alkoxy, halo (C1-C5)alkyl, C2-C5 alkenyl, C1-C5 alkoxycarbonyl, C1-C5 alkylthio, phenyl or phenyl (C1-C3)alkyl, wherein each phenyl group is non-substituted or substituted with at least one substituent, and R13 is H, amino, C1-C5 alkyl, C2-C5 alkenyl, C1-C5 alkoxy, halo(C1-C5)alkyl, trifluoromethyl, phenyl or phenyl(C1-C3)alkyl.
    • 提供作为香草素受体拮抗剂的化合物以获得有效预防或治疗疼痛,偏头痛,关节痛,神经损伤,皮肤疾病,膀胱过度活动症,肠易激综合征等的药物组合物。 作为香草酸受体拮抗剂的化合物,其异构体或其药学上可接受的盐由下式I表示。在式I中,X为NHCH 2,CR 11 = CR 12,NH,CHR 11 CHR 12或C = C,其中R 11和R 12 表示H,卤素,C 1 -C 5烷基,C 1 -C 5烷氧基,卤代(C 1 -C 5)烷基或苯基; R1是C2-C5烯基或C2-C5炔基; R2是H,卤素,硝基,氰基,C1-C5烷基,C1-C5烷氧基,卤代(C1-C5)烷基,C2-C5烯基或C2-C5炔基; R2是H,卤素,硝基,氰基,C1-C5烷基,C1-C5烷氧基,卤代(C1-C5)烷基,C2-C5烯基,C2-C5炔基,羧基,C1-C5烷氧羰基,C1-C5烷硫基, 苯基或苯基(C1-C3)烷基,其中每个苯基是未取代的或被至少一个取代基取代; R3是H,C1-C5烷基,C1-C5烷氧基或卤代(C1-C5)烷基; R 4,R 5,R 6,R 7和R 8各自独立地表示H,羧基,C 1 -C 5烷基,硝基,C 2 -C 5烯基,C 1 -C 5烷氧基,C 2 -C 5炔基,卤代(C 1 -C 5)烷基,C 1 -C 5烷硫基 ,C1-C5烷基磺酰基,C1-C5烷基羰基,C1-C5烷氧基羰基,羟基,C2-C5链烯氧基,C1-C5烷氧基(C1-C5)烷氧基,C1-C5烷氧基(C1-C5)烷氧基(C1-C5)烷基 (C1-C5)烷氧基,C1-C5烷氧基(C1-C5)烷基氨基,C1-C7烷基氨基,吗啉基,吗啉基(C1-C5)烷氧基,四氢吡喃基氧基, 苯基或卤素,其中每个苯基未被取代或被至少一个取代基取代; R 9和R 10各自独立地表示H,-SO 2 R 13,-SOR 13,C 1 -C 5烷基,C 1 -C 5烷氧基,卤代(C 1 -C 5)烷基,C 2 -C 5烯基,C 1 -C 5烷氧基羰基,C 1 -C 5烷硫基,苯基或 苯基(C1-C3)烷基,其中每个苯基未被取代或被至少一个取代基取代,R 13是H,氨基,C 1 -C 5烷基,C 2 -C 5烯基,C 1 -C 5烷氧基,卤代(C1- C5)烷基,三氟甲基,苯基或苯基(C1-C3)烷基。